早期[177Lu]PSMA-617放射配体治疗期间骨髓损伤:血液学毒性还是肿瘤进展?
该回顾性分析纳入64例转移性去势抵抗性前列腺癌患者,在PSMA-RLT两个周期(12-16周)内系统采集血液学参数,并按CTCAE 5.0及PCWG3、PROMISE标准对比生化与影像应答。结果显示所有3/4级血液学不良事件均见于播散性或弥漫性骨受累且生化未应答者;生化未应答者血液学参数百分比显著下降。
要点
- 所有3/4级血液学不良事件均与播散性或弥漫性骨受累及再分期时生化未应答相关。
- 基线时血液学参数与生化及PET体积肿瘤负荷、骨受累模式呈负相关(p≤0.043)。
- 生化未应答者血液学参数百分比显著下降(p≤0.001),生化应答者保持稳定(p≥0.079)。
核心结论
- 早期PSMA-RLT周期中,定性和定量骨髓损伤似乎与骨肿瘤负荷密切相关,仅晚期骨受累且治疗未应答的患者出现高级别血液学不良事件及血液学参数显著下降。
- 在晚期mCRPC患者中,PSMA-RLT未应答可能是早期治疗周期骨髓损伤的主要原因。
研究设计与样本
- 回顾性分析,纳入64例转移性去势抵抗性前列腺癌(mCRPC)患者,在PSMA-RLT两个周期(12-16周)内从基线至再分期系统采集血液学参数。
- 血液学参数变化采用CTCAE 5.0定性分析及定量分析,并与PCWG3和PROMISE标准定义的生化及影像应答进行比较。
- 德国临床试验注册号DRKS00013665,2017年12月28日回顾性注册。
主要发现
- 所有观察到的3/4级血液学不良事件均与播散性或弥漫性骨受累及再分期时生化未应答相关。
- 基线时血液学参数与生化及PET体积肿瘤负荷、骨受累模式呈负相关(p≤0.043)。
- 在播散性或弥漫性骨受累患者中,再分期时血液学参数百分比变化与血清学及影像肿瘤负荷呈负相关(p≤0.017)。
- 生化未应答者血液学参数百分比显著下降(p≤0.001),生化应答者血液学参数保持稳定(p≥0.079)。
关键数值与推荐
- 血液学不良事件按CTCAE 5.0分级。
- 生化与影像应答分别采用PCWG3和PROMISE标准评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recent phase III VISION-trial confirms the treatment efficacy of radioligand therapy with [177Lu]PSMA-617 (PSMA-RLT) in metastatic castration-resistant prostate cancer (mCRPC). In PSMA-RLT, the relatively low absorbed bone marrow dose allows for multiple therapy cycles with relatively low risk of haematological adverse events (hAE). However, as disease progression itself may be a cause of bone marrow impairment, the aim of this study was to assess potential relations between impairment of haematological status and response to PSMA-RLT. METHODS: In this retrospective analysis, haematological parameters (HP) of 64 patients with mCRPC were systematically acquired over two cycles (12-16 weeks) of PSMA-RLT from baseline to restaging. Changes in HP were analysed qualitatively (CTCAE 5.0) and quantitatively. The HP changes from baseline were compared to quantitative and qualitative biochemical and imaging response, using PCWG3 and PROMISE criteria. RESULTS: All grade 3/4 hAE observed were associated with disseminated or diffuse bone involvement as well as biochemical non-response at restaging. Quantitatively, at baseline, HP inversely correlated with biochemical and volumetric (on PET) tumour burden as well as bone involvement pattern (p ≤ 0.043). Among patients with disseminated or diffuse bone involvement, percentage changes in HP (%HP) at restaging inversely correlated with serological and imaging tumour burden (p ≤ 0.017). Biochemical non-responders showed a significant decrease in %HP (p ≤ 0.001) while HP in biochemical responders remained stable (p ≥ 0.079). CONCLUSION: During early cycles of PSMA-RLT, qualitative and quantitative bone marrow impairment appears to be closely associated with osseous tumour burden as only patients with advanced bone involvement and non-response to therapy exhibited high-grade haematological adverse events, showing a significant decline of haematological parameters. This implies that in patients with advanced mCRPC, non-response to PSMA-RLT may be a major cause of bone marrow impairment during early treatment cycles. German Clinical Trial Register DRKS00013665. Registered 28 December 2017, retrospectively registered ( www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00013665 ).
引用
- Kind F, Michalski K, Yousefzadeh-Nowshahr E, et al. Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression? EJNMMI Res. 2022. PMID: 35403915. doi:10.1186/s13550-022-00891-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。